The actual truth is out about Actos: it’s a really bad actor

What do regulators in France and Germany know that the FDA doesn’t?

If we could answer that question, we might uncover how in the world the type 2 diabetes med Actos has managed to keep selling in the U.S. while banned in those other countries.

For years now, the FDA has been hemming and hawing over whether or not Actos ups your risk of bladder cancer.

And even while slapping a warning about that on the Actos label five years ago, it still claimed it wasn’t sure!

But now, even the FDA can’t hold back the news any longer. It finally settled it.

After over a decade of studies and years of reviews, it just announced that yes, the drug “may be linked to an increased risk of bladder cancer.” That may not sound like such a big deal, but for the FDA, it’s humongous.

So, if you’ve been prescribed pioglitazone (the drug’s generic name), now is the time to have a heart-to-heart with your doctor about getting and staying off of it.

Too big to ban

Eight months ago, I told you about a 13-year review that found the diabetes drug Actos can up your risk of bladder cancer by a whopping 63 percent.

This wasn’t a tiny 10-person study, either. The researchers looked at over 145,000 diabetics before they came to that conclusion.

And what did the FDA do with that information? It sat on its hands until the beginning of December before it made its announcement.

But if there ever was a drug that should have been banned years ago, pioglitazone – in all its forms – is it.

Back in April, the senior author of this big study said that this med has “known potential” risks that include fractures, damage to the heart and “now bladder cancer.” It looks like “the pendulum is tilting more toward risk than benefit,” he said.

While that may be the understatement of the year, at least he got the news out.

But that news came too late for thousands of Actos users who got cancer.

One, Terrence Allen, a diabetic diagnosed with bladder cancer after he took Actos for seven years, claimed in a lawsuit that drugmakers Takeda Pharmaceutical and Eli Lilly knew all about the risk, but hid it from doctors and patients so sales wouldn’t be affected.

Apparently the jury believed the evidence that was presented, because they awarded Allen 9 billion dollars.

While that was later reduced to $37 million, Takeda still had to fork over billions to pay off thousands of others like Allen. Experts said they got away with a “bargain.”

But those with type 2 aren’t the only ones in the Actos crosshairs, despite this new warning.

Unbelievably, just this year a group of Yale researchers decided to find out if Actos could lower the risk of non-diabetics having a second stroke or heart attack. And the conclusion?

The lead researcher said he was excited to report that the drug has been “proven to have cardiovascular benefits,” and may be “poised to take its place” beside aspirin and statins to prevent strokes!

And he said that while also admitting that if 100 people took Actos daily for five straight years, three would be saved from having a heart attack or stroke, BUT two would “be expected” to suffer a bone fracture needing surgery. And on top of that, this group didn’t even drop a hint about the med’s bladder-cancer risk in their study.

Seriously? I mean how is it possible to believe articles about these miraculous drug findings that are based on half-truths and that fail to mention key information?

That’s why it’s more important than ever to do our own research and not take the word of these so-called experts, whether they come from Yale or anywhere else.

So please, if you’re currently taking Actos or a combo pill or generic of pioglitazone, ask your doctor to take you off of it.

“FDA still sees bladder cancer risk with pioglitazone” Robert Lowes, December 12, 2016, Medscape,
And if you’re not, keep it that way.

“FDA still sees bladder cancer risk with pioglitazone” Robert Lowes, December 12, 2016, Medscape,